title: Patients with peripheral artery disease undergoing percutaneous peripheral interventions are at increased risk for complications without adequate anticoagulation.
abstract: Percutaneous peripheral interventions (PPI) are often complex procedures performed on high-risk patients with a significant thrombus burden. Although there is no approved anticoagulant for use in PPI, heparin is commonly used but is associated with several limitations. The APPROVE data provide a foundation for further study of bivalirudin in the setting of PPI.
authors.affiliation: Cardiovascular Institute of the South, Lafayette, Louisiana, USA.
authors.forename: David E
authors.initials: DE
authors.lastname: Allie
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage*; D003251:Constriction, Pathologic; D057510:Endovascular Procedures; D006493:Heparin / Q000008:administration & dosage; D006629:Hirudins / Q000008:administration & dosage; D006801:Humans; D007083:Iliac Artery / Q000473:pathology; D010446:Peptide Fragments / Q000008:administration & dosage; D058729:Peripheral Arterial Disease / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012078:Renal Artery Obstruction / Q000188:drug therapy
chemical_list: D000925:Anticoagulants; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin